Literature DB >> 28070534

Design and Construction of a Cloning Vector Containing the hspX Gene of Mycobacterium tuberculosis.

Atieh Yaghoubi1, Ehsan Aryan1, Hosna Zare1, Shadi Alami1, Roghayeh Teimourpour2, Zahra Meshkat1.   

Abstract

BACKGROUND: Tuberculosis (TB) is a major cause of death worldwide. Finding an effective vaccine against TB is the best way to control it. Several vaccines against this disease have been developed but none are completely protective. The aim of this study was to design and construct a cloning vector containing the Mycobacterium tuberculosis (M. tuberculosis) heat shock protein X (hspX).
METHODS: First, an hspX fragment was amplified by PCR and cloned into plasmid pcDNA3.1(+) and recombinant vector was confirmed.
RESULTS: A 435 bp hspX fragment was isolated. The fragment was 100% homologous with hspX of M. tuberculosis strain H37Rv in GenBank.
CONCLUSION: In this study, the cloning vector pcDNA3.1(+), containing a 435-bp hspX fragment of M. tuberculosis, was constructed. This could be used as a DNA vaccine to induce immune responses in animal models in future studies.

Entities:  

Keywords:  Cloning; DNA vaccine; Mycobacterium tuberculosis; hspX

Year:  2016        PMID: 28070534      PMCID: PMC5214683     

Source DB:  PubMed          Journal:  Rep Biochem Mol Biol        ISSN: 2322-3480


  21 in total

1.  Enhanced protection against tuberculosis by vaccination with recombinant BCG over-expressing HspX protein.

Authors:  Chunwei Shi; Lingxia Chen; Zhenhua Chen; Ying Zhang; Zhiguang Zhou; Jia Lu; Ruiling Fu; Chun Wang; Zhengming Fang; Xionglin Fan
Journal:  Vaccine       Date:  2010-06-09       Impact factor: 3.641

Review 2.  Current status of TB vaccines.

Authors:  Umesh Datta Gupta; Vishwa Mohan Katoch; David N McMurray
Journal:  Vaccine       Date:  2007-02-16       Impact factor: 3.641

3.  HspX vaccination and role in virulence in the guinea pig model of tuberculosis.

Authors:  Agatha E Wieczorek; Jolynn L Troudt; Phillip Knabenbauer; Jennifer Taylor; Rebecca L Pavlicek; Russell Karls; Anne Hess; Rebecca M Davidson; Michael Strong; Helle Bielefeldt-Ohmann; Angelo A Izzo; Karen M Dobos
Journal:  Pathog Dis       Date:  2014-02-24       Impact factor: 3.166

4.  APC targeting enhances immunogenicity of a novel multistage Fc-fusion tuberculosis vaccine in mice.

Authors:  Saman Soleimanpour; Hadi Farsiani; Arman Mosavat; Kiarash Ghazvini; Mohammad Reza Akbari Eydgahi; Mojtaba Sankian; Hamid Sadeghian; Zahra Meshkat; Seyed Abdolrahim Rezaee
Journal:  Appl Microbiol Biotechnol       Date:  2015-09-15       Impact factor: 4.813

5.  A multicistronic DNA vaccine induces significant protection against tuberculosis in mice and offers flexibility in the expressed antigen repertoire.

Authors:  Fayaz-Ahmad Mir; Stefan H E Kaufmann; Ali Nasser Eddine
Journal:  Clin Vaccine Immunol       Date:  2009-08-05

Review 6.  Tuberculosis vaccine research: the impact of immunology.

Authors:  Lewellys F Barker; Michael J Brennan; Peri K Rosenstein; Jerald C Sadoff
Journal:  Curr Opin Immunol       Date:  2009-06-07       Impact factor: 7.486

7.  Protective immune responses to a recombinant adenovirus type 35 tuberculosis vaccine in two mouse strains: CD4 and CD8 T-cell epitope mapping and role of gamma interferon.

Authors:  Katarina Radosevic; Catharina W Wieland; Ariane Rodriguez; Gerrit Jan Weverling; Ratna Mintardjo; Gert Gillissen; Ronald Vogels; Yasir A W Skeiky; David M Hone; Jerald C Sadoff; Tom van der Poll; Menzo Havenga; Jaap Goudsmit
Journal:  Infect Immun       Date:  2007-05-25       Impact factor: 3.441

8.  HspX-mediated protection against tuberculosis depends on its chaperoning of a mycobacterial molecule.

Authors:  Jennifer L Taylor; Agatha Wieczorek; Andrew R Keyser; Ajay Grover; Rachel Flinkstrom; Russell K Karls; Helle Bielefeldt-Ohmann; Karen M Dobos; Angelo A Izzo
Journal:  Immunol Cell Biol       Date:  2012-07-17       Impact factor: 5.126

9.  Immunogenicity of a fusion protein containing immunodominant epitopes of Ag85C, MPT51, and HspX from Mycobacterium tuberculosis in mice and active TB infection.

Authors:  Eduardo Martins de Sousa; Adeliane Castro da Costa; Monalisa Martins Trentini; João Alves de Araújo Filho; André Kipnis; Ana Paula Junqueira-Kipnis
Journal:  PLoS One       Date:  2012-10-25       Impact factor: 3.240

10.  Adjunctive immunotherapy with α-crystallin based DNA vaccination reduces Tuberculosis chemotherapy period in chronically infected mice.

Authors:  Priyanka Chauhan; Ruchi Jain; Bappaditya Dey; Anil K Tyagi
Journal:  Sci Rep       Date:  2013       Impact factor: 4.379

View more
  1 in total

1.  Bone morphogenetic protein and activin membrane-bound inhibitor overexpression inhibits gastric tumor cell invasion via the transforming growth factor-β/epithelial-mesenchymal transition signaling pathway.

Authors:  Chun-Ling Yuan; Rong Liang; Zhi-Hui Liu; Yong-Qiang Li; Xiao-Ling Luo; Jia-Zhou Ye; Yan Lin
Journal:  Exp Ther Med       Date:  2018-04-20       Impact factor: 2.447

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.